These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34580113)

  • 21. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
    Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V
    Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
    Fraunhoffer N; Hammel P; Conroy T; Nicolle R; Bachet JB; Harlé A; Rebours V; Turpin A; Ben Abdelghani M; Mitry E; Biagi J; Chanez B; Bigonnet M; Lopez A; Evesque L; Lecomte T; Assenat E; Bouché O; Renouf DJ; Lambert A; Monard L; Mauduit M; Cros J; Iovanna J; Dusetti N
    Ann Oncol; 2024 Sep; 35(9):780-791. PubMed ID: 38906254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFIRINOX
    Begg SKS; Birnbaum DJ; Clark JW; Mino-Kenudson M; Wellner UF; Schilling O; Lillemoe KD; Warshaw AL; Castillo CF; Liss AS
    Anticancer Res; 2020 Jul; 40(7):3659-3667. PubMed ID: 32620605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer.
    Karachaliou GS; Lazarou V; Giannis D; Astras G; Moris D; Petrou A
    J BUON; 2020; 25(5):2525-2527. PubMed ID: 33277879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
    Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
    World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
    Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
    Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
    Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
    Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer.
    Ma H; Esfahani SA; Krishna S; Ataeinia B; Zhou IY; Rotile NJ; Weigand-Whittier J; Boice AT; Liss AS; Tanabe KK; Caravan P
    Cancer Res; 2024 Aug; 84(15):2549-2560. PubMed ID: 38759082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer.
    Peng H; James CA; Cullinan DR; Hogg GD; Mudd JL; Zuo C; Takchi R; Caldwell KE; Liu J; DeNardo DG; Fields RC; Gillanders WE; Goedegebuure SP; Hawkins WG
    Clin Cancer Res; 2021 Dec; 27(24):6761-6771. PubMed ID: 34593529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.